HRP20130307T1 - Novi derivati azabiciklo[3.2.0]hept-3-ila, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže - Google Patents
Novi derivati azabiciklo[3.2.0]hept-3-ila, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20130307T1 HRP20130307T1 HRP20130307AT HRP20130307T HRP20130307T1 HR P20130307 T1 HRP20130307 T1 HR P20130307T1 HR P20130307A T HRP20130307A T HR P20130307AT HR P20130307 T HRP20130307 T HR P20130307T HR P20130307 T1 HRP20130307 T1 HR P20130307T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compounds
- group
- accordance
- image
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000002253 acid Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 7
- 239000002585 base Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000000543 intermediate Substances 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- 239000003513 alkali Substances 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000019430 Motor disease Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000028979 Skull fracture Diseases 0.000 claims 1
- 206010041347 Somnambulism Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 206010020765 hypersomnia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Claims (25)
1. Spoj formule (I):
[image]
naznačen time, da:
♦ ALK predstavlja lanac alkilena,
♦ W predstavlja skupinu
[image]
u kojem R i R’, svaki neovisno jedan od drugoga, predstavljaju atom vodika ili ravnu ili razgranan u (C1-C6)alkilnu skupinu po izboru supstituiranu s jednim ili više skupina odabranih od halogena, hidroksi i alkoksi, pri čemu treba razumjeti da:
- određenje "alkilen" označava ravni ili razgranani dvovalentni radikal koji se sastoji od 2 do 6 atoma ugljika,
- određenje "alkoksi" označava alkil-oksi skupinu u kojoj lanac alkila, koji je ravni ili razgranani, sadrži od 1 do 6 atom a ugljika,
njihovi enantiomeri i dijastereoizomeri te također njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
2. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da je W skupina smještena u para položaju.
3. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da ALK predstavlja ravni dvovalentni radikal koji se sastoji od 2 do 4 atoma ugljika, njihovih enantiomera i dijastereoizomera te također njihovih adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom.
4. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da ALK predstavlja skupinu propilena, njihove enantiomere i dijastereoizomere te također njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
5. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W predstavlja skupinu
[image]
njihove enantiomere i dijastereoizomere te također njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
6. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W predstavlja skupinu
[image]
njihove enantiomere i dijastereoizomer te također njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
7. Spojevi formule (I ) u skladu s patentnim zahtjevom 1, naznačeni time, da R i R’, svaki neovisno jedan od drugog, predstavljaju atom vodika, metilnu skupinu ili etilnu skupinu, te skupine po izboru mogu biti supstituirane s metoksi skupinom, njihovim enantiomerima i dijastereoizomerima te također njihovim adicijskim solima s farmaceutski prihvatljivom kiselinom ili lužinom.
8. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W pred stavlja skupinu -CO-NH2, -CO-NH-CH3, -CO-N(CH3)2, -CO-N(CH2CH3)2, -NH- CO-CH3, -N(CH3)-CO-CH3 ili NH-CO-CH2-OCH3, njihove enantiomere i dijastereoizomere te također njihova adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
9. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da su:
- 4-{3-[(1R,5S)-3-azabiciklo[3.2.0]hept-3-il]propoksi}benzamid,
- N-(4-{3-[(1R,5S)-3-azabiciklo[3.2.o]hept-3-il]propoksi}fenil)acetamid,
- 4-{3-[(1R,5S)-3-azabiciklo[3.2.0]hept-3-il]propoksi}-N,N-dimetilbenzamid,
- N-(4-{3-[(1R,5S)-3-azabiciklo[3.2.0]hept-3-il]propoksi}fenil)-N-metilacetamid
I njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
10. Spojevi formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da su:
- 4-{3-[(1R,5S)-3-azabiciklo[3.2.0]hept-3-il]propoksi}benzamid hidroklorid,
- 4-{3-[(1R,5S)-3-azabiciklo[3.2.0]hept-3-il]propoksi}benzamid oksalat,
- 4-{3-[(1R,5S)-3-azabiciklo[3.2.0]hept-3-il]propoksi}benzamid citrat.
11. Postupak za pripravu spojeva formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da je kao početna tvar korišten spoj formule (II):
[image]
pri čemu je W definiran u patentnom zahtjevu 1,
s kojim ju spoj formule (II) kondenziran, p osnovnom mediju, spoj formule (III):
Br-ALK-Cl (III),
pri čemu je ALK definiran za formulu (I), kako bi se dobio spoj formule (IV):
[image]
pri čemu su W i ALK ranije gore definirani, s kojima je kondenziran spoj formule (V):
[image]
kako bi se dobio spoj formule (I) kako je ranije gore definirano:
[image]
koji može biti pročišćen u skladu s uobičajenim tehnikama separacije, konvertiran, ako je poželjno, u svoje adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom i onda se separira, gdje je prikladno, u svoje optičke izomere u skladu s uobičajenim tehnikama separacije.
12. Spojevi sljedeće formule (VI):
[image]
pri čemu je ALK skupina definirana u patentnom zahtjevu 1, za uporabu u sintezi intermedijera za spojeve formule (I/a), posebnim slučajevima kod spojeva formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W predstavlja skupinu -CONRR’, s time da se podrazumijeva kako su W, R i R’ definirani u patentnom zahtjevu 1.
13. Spojevi sljedeće formule (VII):
[image]
pri čemu je ALK skupina definirana u patentnom zahtjevu 1, za uporabu kao sinteza intermedijera za spojeve formule (I/a), posebnim slučajevima kod spojeva formula (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W predstavlja skupinu -CONRR’, s time da se podrazumijeva kako su W, R i R’ kako je definiranu u patentnom zahtjevu k.
14. Spojevi sljedeće formule (VIII):
[image]
pri čemu je ALK skupina definirana u patentnom zahtjevu 1 a R" je ravna ili razgranana (C1-C6)alkilna skupina ili benzilna skupina, za uporabu kao sinteza intermedijera za spojeve formule (I/a), posebnim slučajevima kod spojeva formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W predstavlja skupinu -CONRR’, s time da se podrazumijeva kako su W, R i R’ definirani u patentnom zahtjevu 1.
15. Spojevi formule (IX):
[image]
pri čemu je ALK skupina definirana u patentnom zahtjevu 1,
za uporabu kao sinteza intermedijera za spojeve formule (I/a), posebnim slučajevima kod spojeva formule (I) u skladu s patentnim zahtjevom 1, naznačeni time, da W predstavlja skupinu -CONRR’, kada se podrazumijeva da su W, R i R’ definirani u patentnom zahtjevu 1.
16. Farmaceutski pripravci, naznačeni time, da sadrže aktivno tvar spoja formule (I) u skladu a bilo kojim od patentnih zahtjeva 1 do 10 ili njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom, u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa.
17. Farmaceutski pripravci u skladu s patentnim zahtjevom 16, naznačeni time, da se koriste za liječenje kognitivnih i psiho-bihejvioralnih poremećaja povezanih sa starenjem mozga, s neurodegenerativnim bolestima ili s prijelomima lubanje.
18. Farmaceutski pripravci u skladu s patentnim zahtjevom 17 naznačeni time, da se koriste za liječenje kognitivnih i psiho-bihejvioralnih poremećaja povezanih s Alzlreimerovom bolesti, Parkinsonovom bolesti, Pickovom bolesti, Lewy body demencijom, demencijom frontalnog režnja i subkortikalnom demencijom, fronto temporalnom demencijom, vaskularnom demencijom, Huntingtonovom bolesti i multipla sklerozom.
19. Farmaceutsko pripravci u skladu s patentnim zahtjevom 17, naznačeni time, da se koriste u psiho-bihejvioralnih poremećaja poput primjerice poremećaja spavanja, apatije i anksiozno-depresivnih stanja.
20. Farmaceutski pripravci u skladu s patentnim zahtjevom 19, naznačeni time, da se koriste u liječenju poremećaja spavanja povezanih s Alzheimerovom i Parkinsonovom bolesti.
21. Farmaceutski pripravci u skladu s patentnim zahtjevom 16, naznačeni time, da se koriste u liječenju poremećaja motorike povezane s Parkinsonovom bolesti.
22. Farmaceutski pripravci u skladu s patentnim zahtjevom 16, naznačeni time, da se koriste u liječenju poremećaja raspoloženja, anksiozno-depresivnih stanja, Touretteovog sindroma, šizofrenije i kognitivnih poremećaja te time povezanih poremećaja, boli i također u liječenju poremećaja spavanja, mjesečarenja u snu i poremećaja pažnje uslijed sindroma povećane hiperaktivnosti.
23. Farmaceutski pripravci u skladu s patentnim zahtjevom 22, naznačeni time, da se koriste za liječenje poremećaja spavanja poput primjerice narkolepsije, hipersomnije koja se javlja kod sindroma opstrukcijske apneje tijekom spavanja ili kod sindroma poremećaja pažnje uslijed hiperaktivnosti i također dnevne pospanosti.
24. Udruženje spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da je L-dopa.
25. Udruženje u skladu s patentnim zahtjevom 24, naznačeno time, da se koristi u liječenju kognitivnih poremećaja i poremećaja motorike Parkinsonove bolesti.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0905957A FR2953514B1 (fr) | 2009-12-09 | 2009-12-09 | Nouveaux derives azabicyclo[3.2.0]hept-3-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130307T1 true HRP20130307T1 (hr) | 2013-04-30 |
Family
ID=42133738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130307AT HRP20130307T1 (hr) | 2009-12-09 | 2013-04-04 | Novi derivati azabiciklo[3.2.0]hept-3-ila, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže |
Country Status (44)
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9300625B (sl) * | 1993-12-02 | 2002-02-28 | Basf Aktiengesellschaft | N-substituirani derivati azabicikloheptana, njihova priprava in uporaba |
| DE4341402A1 (de) * | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| DE4427647A1 (de) * | 1994-08-04 | 1996-02-08 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| FR2866647B1 (fr) * | 2004-02-20 | 2006-10-27 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2009
- 2009-12-09 FR FR0905957A patent/FR2953514B1/fr not_active Expired - Fee Related
-
2010
- 2010-11-19 MY MYPI2010005458 patent/MY150598A/en unknown
- 2010-11-21 IL IL209463A patent/IL209463A/en not_active IP Right Cessation
- 2010-11-22 UY UY0001033046A patent/UY33046A/es unknown
- 2010-11-22 JO JO2010408A patent/JO2880B1/en active
- 2010-11-23 SG SG2010085959A patent/SG172543A1/en unknown
- 2010-11-24 CR CR11811A patent/CR11811A/es not_active Application Discontinuation
- 2010-11-25 PE PE2010001083A patent/PE20110542A1/es not_active Application Discontinuation
- 2010-11-25 AU AU2010246426A patent/AU2010246426B2/en not_active Ceased
- 2010-11-26 CL CL2010001309A patent/CL2010001309A1/es unknown
- 2010-11-26 TW TW099141093A patent/TWI419875B/zh not_active IP Right Cessation
- 2010-11-29 CN CN2010105733405A patent/CN102127004B/zh not_active Expired - Fee Related
- 2010-11-29 CO CO10150441A patent/CO6280059A1/es active IP Right Grant
- 2010-11-30 MX MX2010013093A patent/MX2010013093A/es active IP Right Grant
- 2010-12-01 MA MA33380A patent/MA32444B1/fr unknown
- 2010-12-01 ZA ZA2010/08651A patent/ZA201008651B/en unknown
- 2010-12-01 AP AP2010005489A patent/AP2755A/xx active
- 2010-12-01 EC EC2010010649A patent/ECSP10010649A/es unknown
- 2010-12-02 CU CU2010000236A patent/CU23993B1/es not_active IP Right Cessation
- 2010-12-02 NI NI201000206A patent/NI201000206A/es unknown
- 2010-12-02 SV SV2010003746A patent/SV2010003746A/es unknown
- 2010-12-03 CA CA2724151A patent/CA2724151C/fr not_active Expired - Fee Related
- 2010-12-06 UA UAA201014568A patent/UA106721C2/uk unknown
- 2010-12-06 AR ARP100104487A patent/AR079268A1/es unknown
- 2010-12-07 KR KR1020100124116A patent/KR101292705B1/ko not_active IP Right Cessation
- 2010-12-07 SA SA110320007A patent/SA110320007B1/ar unknown
- 2010-12-07 GE GEAP201012026A patent/GEP20135801B/en unknown
- 2010-12-07 NZ NZ589763A patent/NZ589763A/en not_active IP Right Cessation
- 2010-12-07 US US12/928,237 patent/US8008337B2/en not_active Expired - Fee Related
- 2010-12-07 EA EA201001755A patent/EA018971B1/ru not_active IP Right Cessation
- 2010-12-08 DK DK10290642.7T patent/DK2332910T3/da active
- 2010-12-08 ME MEP-2013-42A patent/ME01504B/me unknown
- 2010-12-08 WO PCT/FR2010/000820 patent/WO2011070250A1/fr active Application Filing
- 2010-12-08 ES ES10290642T patent/ES2405206T3/es active Active
- 2010-12-08 BR BRPI1005270-4A patent/BRPI1005270A2/pt not_active IP Right Cessation
- 2010-12-08 RS RS20130092A patent/RS52698B/en unknown
- 2010-12-08 PT PT102906427T patent/PT2332910E/pt unknown
- 2010-12-08 PL PL10290642T patent/PL2332910T3/pl unknown
- 2010-12-08 EP EP10290642A patent/EP2332910B1/fr active Active
- 2010-12-08 HN HN2010002593A patent/HN2010002593A/es unknown
- 2010-12-08 SI SI201030183T patent/SI2332910T1/sl unknown
- 2010-12-09 JP JP2010274280A patent/JP5511645B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-04 HR HRP20130307AT patent/HRP20130307T1/hr unknown
- 2013-04-29 CY CY20131100354T patent/CY1113971T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2544856C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| IL258732A (en) | Salts and their benzene and polymorphs | |
| ES2296162T3 (es) | Derivados de alquilpiperazin- y alquilhomopiperazin- carboxilatos, su preparacion y su aplicacion como inhibidores de la enzima faah. | |
| CA2636324A1 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| JP2009531277A5 (hr) | ||
| JP2004516278A (ja) | 一酸化窒素合成酵素阻害物質であるリン酸塩 | |
| JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
| RU2014145682A (ru) | Органические соединения | |
| JP2021512146A (ja) | キャップ依存性エンドヌクレアーゼ阻害剤 | |
| KR20020063281A (ko) | 3-(2-디메틸아미노메틸-1-하이드록시사이클로헥실)페닐의(ｒｒ,ｓｓ)-2-하이드록시벤조에이트로부터 유래된 신규에스테르 | |
| SA08290715B1 (ar) | صورة بلورية جديدة سادسة من أجوميلاتين، وعملية لتحضيرها والتركيبات الصيدلانية المحتوية عليها | |
| JP2011530521A5 (hr) | ||
| JP2005539045A5 (hr) | ||
| JP2013542267A5 (hr) | ||
| HRP20170539T1 (hr) | Hidroksialifatski supstituirani derivati fenilaminoalkil-etera | |
| JP2012532125A5 (hr) | ||
| WO1995026327A1 (en) | Substituted cycloalkylamine derivatives and their use as calcium channel antagonists | |
| ES2601250T3 (es) | Fármaco activo contra el dolor neuropático | |
| IL196274A (en) | Alcoholic amine history and immunosuppressive factor with the same active ingredient | |
| HRP20130307T1 (hr) | Novi derivati azabiciklo[3.2.0]hept-3-ila, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže | |
| OA13258A (en) | Amino acids with affinity for the alpha2delta-protein. | |
| JP2012526793A (ja) | 酸化還元薬物誘導体 | |
| SK17302002A3 (sk) | Zlúčeniny vhodné na prípravu liekov s inhibičnou aktivitou proti fosfodiesteráze IV | |
| AU2016240069B2 (en) | Indole analogs as 5-oxo-ETE receptor antagonists and method of use thereof | |
| JP2014520785A5 (hr) |